Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

For patients who had 12 months of continuous health care coverage before and after receiving a diagnosis of vitiligo, treatment rates were at suboptimal levels. Using data from the Merative MarketScan ...

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis. Atopic dermatitis (AD) and ...

Vitiligo is a long-term skin condition where certain areas lose their natural color and turn noticeably lighter than the ...

CARLSBAD, Calif. — When patients with vitiligo see Jessica Shiu, MD, PhD, for the first time, some mention that prior healthcare providers have told them that vitiligo is merely a cosmetic issue — ...

I’ve been a vitiligo researcher for almost 20 years. While it affects people of all races and ethnicities equally, it’s more visible in people with darker skin tones. As a result, they may be more ...

The "United States Vitiligo Market Report by Diseases Type, Treatment Type, End User, Regions and Company Analysis, 2025-2033" report has been added to ResearchAndMarkets.com's offering. United States ...

Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...